Author

Yiquan Xu

Observed name: Yi-Quan Xu

Institutions: Fujian Medical University, Fujian Provincial Cancer Hospital

Observed institutions: Fujian Medical University, Shenzhen University, Chinese PLA General Hospital, Fudan University Shanghai Cancer Center, First Affiliated Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Chinese People's Liberation Army

OpenAlex ID: A5100557527

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

2024 · Gen Lin, Zhijie Wang, et al. · Thoracic Cancer · 19

Broadband and ultrafast all‐optical switching based on transition metal carbide

2021 · Cong Wang, Lingfeng Gao, et al. · Nanophotonics · 19

Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma

2022 · Chao Li, Xiaobin Zheng, et al. · Frontiers in Immunology · 15

Inverted Sandwich-Type e-LCR Aided by Lambda Exonuclease-RecJf Combination Enables Ultrasensitive Detection of Low-Frequency EGFR-L858R Mutation in NSCLC

2024 · Tai-Cheng Lu, Yi-Quan Xu, et al. · Analytical Chemistry · 4

Preparation of a Novel Transplant Material, Zirconium Oxide (ZrO₂) Nanotubes, and Characterizations Research

2020 · Chen Wang, Yuchen Wang, et al. · Annals of Transplantation · 4

A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score

2024 · Xinlong Zheng, Tao Lu, et al. · MedComm · 3

Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis

2024 · Qiaofeng Zhong, Longfeng Zhang, et al. · Therapeutic Advances in Medical Oncology · 3

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions

2024 · Haibo Wang, Yiquan Xu, et al. · Cancer Control · 2

Safety and Efficacy of Aumolertinib as First‐Line Treatment in EGFR‐Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single‐Arm, Prospective Phase II Study (ARISE Study)

2026 · Longfeng Zhang, Long Huang, et al. · MedComm

CD8+ T Cell/Cancer-Associated Fibroblasts Ratio Stratifies Prognostic and Predictive Responses to Immunotherapy Across Multiple Cancer Types

2022 · Xinlong Zheng, Kan Jiang, et al. · SSRN Electronic Journal

Works count: 10

Citation count: 69

H-index: 4

I10-index: 3